drugset
drugset / Trial / NCT02887976

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

NCT02887976 ↗

Phase 3 Completed 2 enrolled GU Research Network, LLC Churchill Pharmaceutical LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.

Timeline

Start
2016-09
Primary completion
2017-10-06
Completion
2017-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 500 mg —
Background Methylprednisolone Other / unclassified 4 mg —

Indications

prostate cancer